ELSEVIER

Diabetes Research and Clinical Practice 52 (2001) 223–225

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 52

Ahn, C.W., H.C. Lee, S.W. Park, Y.D. Song, K.B. Huh, S.J. Oh, Y.S. Kim, Y.K. Choi, J.M. Kim, T.H. Lee, Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus **52**, 45
Alberti, K.G.M.M., see Oldroyd, J.C. **52**, 29
Aller, R., see de Luis, D.A. **52**, 1
Amiral, J., see Morcos, M. **52**, 175
Arai, T., see Yamamoto, R. **52**, 213
Arkkila, P.E.T., P.J. Koskinen, I.M. Kantola, T. Rönnemaa, E. Seppänen, J.S. Viikari, Diabetic complications are associated with liver enzyme activities in people with type 1 diabetes **52**, 113

Barrell, G.K., see Dellow, W.J. **52**, 165
Boixeda, D., see de Luis, D.A. **52**, 1
Borcea, V., see Morcos, M. **52**, 175

Caballero, C., see de Luis, D.A. **52**, 1
Cantón, R., see de Luis, D.A. **52**, 1
Chambers, S.T., see Dellow, W.J. **52**, 165
Chin, W., see Naito, J. **52**, 11
Choi, C.S., see Kim, Y.I. **52**, 145
Choi, C.S., see Park, K.S. **52**, 97
Choi, Y.K., see Ahn, C.W. **52**, 45
Chung, S.S.M., see Ng, D.P.K. **52**, 21
Chung, Y.E., see Kim, Y.I. **52**, 145
Clifford, R.M., see Davis, T.M.E. **52**, 63
Conn, J., see Ng, D.P.K. **52**, 21
Coope, P.A., see Florkowski, C.M. **52**, 119
Cordero, J.M., see de Luis, D.A. **52**, 1

Davis, T.M.E., R.M. Clifford, W.A. Davis, Effect of insulin therapy on quality of life in Type 2 diabetes mellitus: The Fremantle Diabetes Study **52**, 63
Davis, W.A., see Davis, T.M.E. **52**, 63
Deepa, R., see Fida, S. **52**, 205
de la Calle, H., see de Luis, D.A. **52**, 1
Dellow, W.J., S.T. Chambers, G.K. Barrell, M. Lever, R.A. Robson, Glycine betaine excretion is not directly linked to plasma glucose concentrations in hyperglycaemia **52**, 165
de Luis, D.A., J.M. Cordero, C. Caballero, D. Boixeda, R. Aller, R. Cantón, H. de la Calle, Effect of the treatment of *Helicobacter pylori* infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus **52**, 1
Deshpande, M., see Sitasawad, S. **52**, 77
de Vries, H., see Pijls, L.T.J. **52**, 133
Dong, H., N. Morral, R. McEvoy, M. Meseck, S.N. Thung, S.L.C. Woo, Hepatic insulin expression improves glycemic control in type 1 diabetic rats **52**, 153
Donker, A.J.M., see Pijls, L.T.J. **52**, 133

Ehret, T., see Morcos, M. **52**, 175

Fida, S., M. Myers, I.R. Mackay, P.Z. Zimmet, V. Mohan, R. Deepa, M.J. Rowley, Antibodies to diabetes-associated autoantigens in Indian patients with Type 1 diabetes: prevalence of anti-ICA512/IA2 and anti-SOX13 **52**, 205
Florkowski, C.M., R.S. Scott, P.A. Coope, P.J. Graham, C.L. Moir, Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of Type 1 diabetic subjects in Canterbury, New Zealand **52**, 119

Gehrke, S., see Morcos, M. **52**, 175
G. Larkins, R., see Ng, D.P.K. **52**, 21
Graham, P.J., see Florkowski, C.M. **52**, 119

Hanafusa, T., see Zhu, Q. **52**, 171
Haneda, M., see Hayashi, K. **52**, 85
Hayashi, K., M. Haneda, D. Koya, S. Maeda, K. Isshiki, R. Kikkawa, Enhancement of glomerular heme oxygenase-1 expression in diabetic rats **52**, 85
Heine, R.J., see van der Wal, P.S. **52**, 103
Henkels, M., see Morcos, M. **52**, 175
Hirao, K., see Yamamoto, R. **52**, 213
Hofmann, M., see Morcos, M. **52**, 175
Hong, S.K., see Kim, Y.I. **52**, 145
Hori, M., see Imano, E. **52**, 185
Huh, K.B., see Ahn, C.W. **52**, 45

PII: S0168-8227(00)00258-3

Imano, E., T. Miyatsuka, M. Motomura, T. Kanda, M. Matsuhisa, Y. Kajimoto, Y. Yamasaki, M. Hori, Heart rate elevation and diabetic retinopathy in patients with type 2 diabetes mellitus and normoalbuminuria **52**, 185
Imrie, K., see Oldroyd, J.C. **52**, 29
Inoue, M., see Naito, J. **52**, 11
Isermann, B., see Morcos, M. **52**, 175
Ishioka, T., see Mishima, Y. **52**, 119
Isshiki, K., see Hayashi, K. **52**, 85

Kajimoto, Y., see Imano, E. **52**, 185
Kanda, T., see Imano, E. **52**, 185
Kantola, I.M., see Arkkila, P.E.T. **52**, 113
Katdare, M., see Sitasawad, S. **52**, 77
Kibata, M., see Mishima, Y. **52**, 119
Kikkawa, R., see Hayashi, K. **52**, 85
Kim, C.-H., see Kim, Y.I. **52**, 145
Kim, J.M., see Ahn, C.W. **52**, 45
Kim, S.K., see Park, K.S. **52**, 97
Kim, Y.I., C.-H. Kim, C.S. Choi, Y.E. Chung, M.S. Lee, S.I. Lee, J.Y. Park, S.K. Hong, K.-U. Lee, Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population **52**, 145
Kim, Y.S., see Ahn, C.W. **52**, 45
Kinoshita, T., see Yamamoto, R. **52**, 213
Koh, J.J., see Park, K.S. **52**, 97
Koretsune, Y., see Naito, J. **52**, 11
Koskinen, P.J., see Arkkila, P.E.T. **52**, 113
Koya, D., see Hayashi, K. **52**, 85
Kriegsman, D.M.W., see Pijls, L.T.J. **52**, 133
Kusuoka, H., see Naito, J. **52**, 11
Kuyama, A., see Mishima, Y. **52**, 119

Lee, H.C., see Ahn, C.W. **52**, 45
Lee, H.K., see Park, K.S. **52**, 97
Lee, K.-U., see Kim, Y.I. **52**, 145
Lee, K.-U., see Park, K.S. **52**, 97
Lee, M.S., see Kim, Y.I. **52**, 145
Lee, S.I., see Kim, Y.I. **52**, 145
Lee, T.H., see Ahn, C.W. **52**, 45
Lever, M., see Dellow, W.J. **52**, 165
Liu, W., see Zhu, Q. **52**, 171

Mackay, I.R., see Fida, S. **52**, 205
Maeda, S., see Hayashi, K. **52**, 85
Mathers, J.C., see Oldroyd, J.C. **52**, 29
Matsuhisa, M., see Imano, E. **52**, 185
Matsuzawa, Y., see Zhu, Q. **52**, 171
McEvoy, R., see Dong, H. **52**, 153
Mertes, G., Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study **52**, 193
Meseck, M., see Dong, H. **52**, 153
Mira, M., see Overland, J. **52**, 55
Mishima, Y., A. Kuyama, A. Tada, K. Takahashi, T. Ishioka, M. Kibata, Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus **52**, 119
Miyagawa, J., see Zhu, Q. **52**, 171
Miyatsuka, T., see Imano, E. **52**, 185
Mohan, V., see Fida, S. **52**, 205
Moir, C.L., see Florkowski, C.M. **52**, 119
Momoki, T., see Yamamoto, R. **52**, 213
Morcos, M., V. Borcea, B. Isermann, S. Gehrke, T. Ehret, M. Henkels, S. Schiekofer, M. Hofmann, J. Amiral, H. Tritschler, R. Ziegler, P. Wahl, P.P. Nawroth, Effect of α-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study **52**, 175
Morral, N., see Dong, H. **52**, 153
Motomura, M., see Imano, E. **52**, 185
Myers, M., see Fida, S. **52**, 205

Naito, J., Y. Koretsune, N. Sakamoto, R. Shutta, J. Yoshida, Y. Yasuoka, S. Yoshida, W. Chin, H. Kusuoka, M. Inoue, Transmural heterogeneity of myocardial integrated backscatter in diabetic patients without overt cardiac disease **52**, 11
Nawroth, P.P., see Morcos, M. **52**, 175
Ng, D.P.K., J. Conn, S.S.M. Chung, R. G. Larkins, Aldose reductase $(AC)_n$ microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus **52**, 21

Oh, S.J., see Ahn, C.W. **52**, 45
Okamura, A., see Yamamoto, R. **52**, 213
Oldroyd, J.C., N.C. Unwin, M. White, K. Imrie, J.C. Mathers, K.G.M.M. Alberti, Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months **52**, 29
Overland, J., D.K. Yue, M. Mira, Continuity of care in diabetes: to whom does it matter? **52**, 55

Parab, P., see Sitasawad, S. **52**, 77
Park, D.J., see Park, K.S. **52**, 97
Park, J.Y., see Kim, Y.I. **52**, 145
Park, K.S., K.-U. Lee, J.H. Song, C.S. Choi, C.S. Shin, D.J. Park, S.K. Kim, J.J. Koh, H.K. Lee, Peripheral blood mitochondrial DNA content is inversely correlated with insulin secretion during hyperglycemic clamp studies in healthy young men **52**, 97
Park, S.W., see Ahn, C.W. **52**, 45
Pijls, L.T.J., H. de Vries, D.M.W. Kriegsman, A.J.M. Donker, J.T.M. van Eijk, Determinants of albuminuria in people with Type 2 diabetes mellitus **52**, 133

Robson, R.A., see Dellow, W.J. **52**, 165
Rönnemaa, T., see Arkkila, P.E.T. **52**, 113
Rowley, M.J., see Fida, S. **52**, 205

Sakamoto, N., see Naito, J. **52**, 11
Schiekofer, S., see Morcos, M. **52**, 175

Scott, R.S., see Florkowski, C.M. **52**, 119
Sekihara, H., see Yamamoto, R. **52**, 213
Seppänen, E., see Arkkila, P.E.T. **52**, 113
Shin, C.S., see Park, K.S. **52**, 97
Shutta, R., see Naito, J. **52**, 11
Sitasawad, S., M. Deshpande, M. Katdare, S. Tirth, P. Parab, Beneficial effect of supplementation with copper sulfate on STZ-diabetic mice (IDDM) **52**, 77
Song, J.H., see Park, K.S. **52**, 97
Song, Y.D., see Ahn, C.W. **52**, 45

Tada, A., see Mishima, Y. **52**, 119
Takahashi, K., see Mishima, Y. **52**, 119
Thung, S.N., see Dong, H. **52**, 153
Tirth, S., see Sitasawad, S. **52**, 77
Tritschler, H., see Morcos, M. **52**, 175
Tsukahara, Y., see Zhu, Q. **52**, 171

Unwin, N.C., see Oldroyd, J.C. **52**, 29

van der Wal, P.S., R.J. Heine, Characteristics of pancreatic β-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide **52**, 103
van Eijk, J.T.M., see Pijls, L.T.J. **52**, 133
Viikari, J.S., see Arkkila, P.E.T. **52**, 113

Wahl, P., see Morcos, M. **52**, 175
White, M., see Oldroyd, J.C. **52**, 29
Woo, S.L.C., see Dong, H. **52**, 153

Yamagata, K., see Zhu, Q. **52**, 171
Yamamoto, R., T. Kinoshita, T. Momoki, T. Arai, A. Okamura, K. Hirao, H. Sekihara, Postural sway and diabetic peripheral neuropathy **52**, 213
Yamasaki, Y., see Imano, E. **52**, 185
Yang, Q., see Zhu, Q. **52**, 171
Yasuoka, Y., see Naito, J. **52**, 11
Yoshida, J., see Naito, J. **52**, 11
Yoshida, S., see Naito, J. **52**, 11
Yue, D.K., see Overland, J. **52**, 55

Zhu, Q., K. Yamagata, Y. Tsukahara, Q. Yang, W. Liu, T. Hanafusa, J. Miyagawa, Y. Matsuzawa, Mutation screening of the hepatocyte nuclear factor (HNF)-6 gene in Japanese subjects with diabetes mellitus **52**, 171
Ziegler, R., see Morcos, M. **52**, 175
Zimmet, P.Z., see Fida, S. **52**, 205

ELSEVIER

Diabetes Research and Clinical Practice 52 (2001) 227–230

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 52

Acarbose; Type 2 diabetes; Surveillance study **52**, 193

Adenoviral vector; Type 1 diabetes; Hyperglycemia; Hepatic insulin production; Nude rats **52**, 153

Alanine amino transferase; LJM; Retinopathy; Neuropathy; γ-glutamyl transferase; Alkaline phosphatase **52**, 113

Albuminuria; Type 2 diabetes mellitus; Anthropometry; Blood pressure; Dietary proteins; Glycosuria; Smoking **52**, 133

Aldose reductase; Diabetic microvascular complications; Genetic susceptibility; Polymorphism; Type 1 diabetes **52**, 21

Alkaline phosphatase; LJM; Retinopathy; Neuropathy; Alanine amino transferase; γ-glutamyl transferase **52**, 113

Ambulatory blood pressure monitoring; Diabetic retinopathy; Heart rate; Type 2 diabetes mellitus; Urinary albumin excretion **52**, 185

Anthropometry; Albuminuria; Type 2 diabetes mellitus; Blood pressure; Dietary proteins; Glycosuria; Smoking **52**, 133

Antioxidant enzymes; Diabetic nephropathy; Oxidative stress; Heme oxygenase-1; Vitamin E **52**, 85

Atherosclerosis; Intima media thickness; Common carotid artery; Diabetes; Cilostazol **52**, 45

Blood pressure; Albuminuria; Type 2 diabetes mellitus; Anthropometry; Dietary proteins; Glycosuria; Smoking **52**, 133

Central obesity; Hyperinsulinemia; Insulin resistance syndrome; Korean; Microalbuminuria **52**, 145

Cilostazol; Intima media thickness; Common carotid artery; Atherosclerosis; Diabetes **52**, 45

Common carotid artery; Intima media thickness; Atherosclerosis; Diabetes; Cilostazol **52**, 45

Complications; Continuity of care; Primary care **52**, 55

Continuity of care; Primary care; Complications **52**, 55

Copper sulfate; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

Coronary heart disease; Impaired glucose tolerance; Diet; Physical activity; Type 2 diabetes **52**, 29

Diabetes; Intima media thickness; Common carotid artery; Atherosclerosis; Cilostazol **52**, 45

Diabetes mellitus; α-lipoic acid; Thrombomodulin; Microvascular diabetic complications **52**, 175

Diabetes mellitus; Ultrasonic tissue characterization; Integrated backscatter; Transmural heterogeneity; Diabetic cardiomyopathy **52**, 11

Diabetes quality of life questionnaire; Quality of life; Insulin treatment; Type 2 diabetes; Rosser index **52**, 63

Diabetic cardiomyopathy; Diabetes mellitus; Ultrasonic tissue characterization; Integrated backscatter; Transmural heterogeneity **52**, 11

Diabetic microvascular complications; Aldose reductase; Genetic susceptibility; Polymorphism; Type 1 diabetes **52**, 21

Diabetic nephropathy; Oxidative stress; Heme oxygenase-1; Antioxidant enzymes; Vitamin E **52**, 85

PII: S0168-8227(00)00259-5

Diabetic neuropathy; Type 2 diabetes; Postural sway; Gravicorder **52**, 213

Diabetic retinopathy; Heart rate; Ambulatory blood pressure monitoring; Type 2 diabetes mellitus; Urinary albumin excretion **52**, 185

Diabetic; Type 2; Gliclazide; Glibenclamide **52**, 103

Dietary proteins; Albuminuria; Type 2 diabetes mellitus; Anthropometry; Blood pressure; Glycosuria; Smoking **52**, 133

Diet; Impaired glucose tolerance; Physical activity; Type 2 diabetes; Coronary heart disease **52**, 29

Fibrocalculous pancreatic diabetes (FCPD); Type 1 diabetes; Type 2 diabetes; ICA512/IA2; SOX13 **52**, 205

Gastric emptying; *Helicobacter pylori* infection; Type 1 diabetes mellitus **52**, 1

Genetics; MODY; HNF-6 **52**, 171

Genetic susceptibility; Aldose reductase; Diabetic microvascular complications; Polymorphism; Type 1 diabetes **52**, 21

Glibenclamide; Type 2; Diabetic; Gliclazide **52**, 103

Gliclazide; Type 2; Diabetic; Glibenclamide **52**, 103

Glucose; Urine osmolality; Organic osmolytes **52**, 165

γ-glutamyl transferase; LJM; Retinopathy; Neuropathy; Alanine amino transferase; Alkaline phosphatase **52**, 113

Glycosuria; Albuminuria; Type 2 diabetes mellitus; Anthropometry; Blood pressure; Dietary proteins; Smoking **52**, 133

Gravicorder; Type 2 diabetes; Postural sway; Diabetic neuropathy **52**, 213

Heart rate; Diabetic retinopathy; Ambulatory blood pressure monitoring; Type 2 diabetes mellitus; Urinary albumin excretion **52**, 185

***Helicobacter pylori* infection**; Gastric emptying; Type 1 diabetes mellitus **52**, 1

Heme oxygenase-1; Diabetic nephropathy; Oxidative stress; Antioxidant enzymes; Vitamin E **52**, 85

Hepatic insulin production; Type 1 diabetes; Hyperglycemia; Adenoviral vector; Nude rats **52**, 153

HNF-6; MODY; Genetics **52**, 171

Hyperglycemia; Type 1 diabetes; Hepatic insulin production; Adenoviral vector; Nude rats **52**, 153

Hyperglycemic clamp; Mitochondrial DNA; Insulin secretion; Insulin resistance **52**, 97

Hyperinsulinemia; Central obesity; Insulin resistance syndrome; Korean; Microalbuminuria **52**, 145

ICA512/IA2; Type 1 diabetes; Type 2 diabetes; Fibrocalculous pancreatic diabetes (FCPD); SOX13 **52**, 205

Impaired glucose tolerance; Diet; Physical activity; Type 2 diabetes; Coronary heart disease **52**, 29

Inducible nitric oxide synthase; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; γ-interferon; Interleukin-4 **52**, 77

Insulin-dependent diabetes mellitus; Streptozotocin; Pancreatic β-cells; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

Insulin resistance; Mitochondrial DNA; Insulin secretion; Hyperglycemic clamp **52**, 97

Insulin resistance syndrome; Central obesity; Hyperinsulinemia; Korean; Microalbuminuria **52**, 145

Insulin resistance; Tumor necrosis factor-α; Type 2 diabetes mellitus; Obesity **52**, 119

Insulin secretion; Mitochondrial DNA; Insulin resistance; Hyperglycemic clamp **52**, 97

Insulin treatment; Quality of life; Type 2 diabetes; Diabetes quality of life questionnaire; Rosser index **52**, 63

Integrated backscatter; Diabetes mellitus; Ultrasonic tissue characterization; Transmural heterogeneity; Diabetic cardiomyopathy **52**, 11

γ-interferon; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; Interleukin-4 **52**, 77

Interleukin-4; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; γ-interferon **52**, 77

Intima media thickness; Common carotid artery; Atherosclerosis; Diabetes; Cilostazol **52**, 45

Korean; Central obesity; Hyperinsulinemia; Insulin resistance syndrome; Microalbuminuria **52**, 145

Lipid peroxidation; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Copper sulfate; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

α-lipoic acid; Diabetes mellitus; Thrombomodulin; Microvascular diabetic complications **52**, 175

LJM; Retinopathy; Neuropathy; Alanine amino transferase; γ-glutamyl transferase; Alkaline phosphatase **52**, 113

Microalbuminuria; Central obesity; Hyperinsulinemia; Insulin resistance syndrome; Korean **52**, 145

Microvascular diabetic complications; Diabetes mellitus; α-lipoic acid; Thrombomodulin **52**, 175

Mitochondrial DNA; Insulin secretion; Insulin resistance; Hyperglycemic clamp **52**, 97

MODY; HNF-6; Genetics **52**, 171

Neuropathy; LJM; Retinopathy; Alanine amino transferase; γ-glutamyl transferase; Alkaline phosphatase **52**, 113

Nude rats; Type 1 diabetes; Hyperglycemia; Hepatic insulin production; Adenoviral vector **52**, 153

Obesity; Tumor necrosis factor-α; Type 2 diabetes mellitus; Insulin resistance **52**, 119

Organic osmolytes; Glucose; Urine osmolality **52**, 165

Oxidative stress; Diabetic nephropathy; Heme oxygenase-1; Antioxidant enzymes; Vitamin E **52**, 85

Pancreatic β-cells; Streptozotocin; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

Physical activity; Impaired glucose tolerance; Diet; Type 2 diabetes; Coronary heart disease **52**, 29

Polymorphism; Aldose reductase; Diabetic microvascular complications; Genetic susceptibility; Type 1 diabetes **52**, 21

Postural sway; Type 2 diabetes; Gravicorder; Diabetic neuropathy **52**, 213

Primary care; Continuity of care; Complications **52**, 55

Quality of life; Insulin treatment; Type 2 diabetes; Diabetes quality of life questionnaire; Rosser index **52**, 63

Reactive oxygen intermediates; Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

Retinopathy; LJM; Neuropathy; Alanine amino transferase; γ-glutamyl transferase; Alkaline phosphatase **52**, 113

Retinopathy; Type 1 diabetes **52**, 119

Rosser index; Quality of life; Insulin treatment; Type 2 diabetes; Diabetes quality of life questionnaire **52**, 63

Smoking; Albuminuria; Type 2 diabetes mellitus; Anthropometry; Blood pressure; Dietary proteins; Glycosuria **52**, 133

SOX13; Type 1 diabetes; Type 2 diabetes; Fibrocalculous pancreatic diabetes (FCPD); ICA512/IA2 **52**, 205

Streptozotocin; Pancreatic β-cells; Insulin-dependent diabetes mellitus; Reactive oxygen intermediates; Lipid peroxidation; Copper sulfate; Inducible nitric oxide synthase; γ-interferon; Interleukin-4 **52**, 77

Surveillance study; Acarbose; Type 2 diabetes **52**, 193

Thrombomodulin; Diabetes mellitus; α-lipoic acid; Microvascular diabetic complications **52**, 175

Transmural heterogeneity; Diabetes mellitus; Ultrasonic tissue characterization; Integrated backscatter; Diabetic cardiomyopathy **52**, 11

Tumor necrosis factor-α; Type 2 diabetes mellitus; Insulin resistance; Obesity **52**, 119

Type 2 diabetes; Acarbose; Surveillance study **52**, 193

Type 1 diabetes; Aldose reductase; Diabetic microvascular complications; Genetic susceptibility; Polymorphism **52**, 21

Type 1 diabetes; Hyperglycemia; Hepatic insulin production; Adenoviral vector; Nude rats **52**, 153

Type 2 diabetes; Impaired glucose tolerance; Diet; Physical activity; Coronary heart disease **52**, 29

Type 2 diabetes mellitus; Albuminuria; Anthropometry; Blood pressure; Dietary proteins; Glycosuria; Smoking **52**, 133

Type 2 diabetes mellitus; Diabetic retinopathy; Heart rate; Ambulatory blood pressure monitoring; Urinary albumin excretion **52**, 185

Type 1 diabetes mellitus; Gastric emptying; *Helicobacter pylori* infection **52**, 1

Type 2 diabetes mellitus; Tumor necrosis factor-α; Insulin resistance; Obesity **52**, 119

Type 2 diabetes; Postural sway; Gravicorder; Diabetic neuropathy **52**, 213

Type 2 diabetes; Quality of life; Insulin treatment; Diabetes quality of life questionnaire; Rosser index **52**, 63

Type 1 diabetes; Retinopathy **52**, 119

Type 2 diabetes; Type 1 diabetes; Fibrocalculous pancreatic diabetes (FCPD); ICA512/IA2; SOX13 **52**, 205

Type 1 diabetes; Type 2 diabetes; Fibrocalculous pancreatic diabetes (FCPD); ICA512/IA2; SOX13 **52**, 205

Type 2; Diabetic; Gliclazide; Glibenclamide **52**, 103

Ultrasonic tissue characterization; Diabetes mellitus; Integrated backscatter; Transmural heterogeneity; Diabetic cardiomyopathy **52**, 11

Urinary albumin excretion; Diabetic retinopathy; Heart rate; Ambulatory blood pressure monitoring; Type 2 diabetes mellitus **52**, 185

Urine osmolality; Glucose; Organic osmolytes **52**, 165

Vitamin E; Diabetic nephropathy; Oxidative stress; Heme oxygenase-1; Antioxidant enzymes **52**, 85